Testosterone & Testosterone-Derived Performance Enhancement (Esters, Transdermals & Prohormones)

1. Generic or Accepted Substance Name & Classifications

Accepted Name: Testosterone & Testosterone-Derived Performance Enhancement (Esters, Transdermals & Prohormones)
Common Names, Synonyms & Classifications: Testosterone Enanthate; Testosterone Cypionate; Testosterone Propionate; Testosterone Undecanoate IP; Androstenedione; DHEA (Dehydroepiandrosterone); Epitestosterone
Section Classification: Group B — Pharmacological & Prohibited Performance-Enhancing Substances (PERF-B20)

2. Pharmacological Class

Principal Endogenous Androgenic-Anabolic Steroid Hormone (17beta-Hydroxyandrost-4-en-3-one) & Steroid Precursors

3. Mechanism of Action

Endogenous C19 steroid hormone synthesised primarily by testicular Leydig cells under pituitary LH stimulation. Testosterone binds directly to intracellular Androgen Receptors (AR) and undergoes local 5-alpha-reduction (via 5-alpha-reductase Types I/II) to the more potent dihydrotestosterone (DHT) and aromatisation (via CYP19A1 aromatase) to 17beta-oestradiol. Exogenous administration suppresses hypothalamic GnRH and pituitary LH/FSH, shutting down endogenous Leydig-cell steroidogenesis and intratesticular spermatogenesis.

4. Proposed Performance or Endurance Effects (Pharmacological Effect vs Proven Athletic Outcome)

Pharmacological Effect: Dose-dependent stimulation of myonuclei accretion, myofibrillar protein synthesis, and renal erythropoietin/hepcidin suppression. Anti-Doping & Clinical Reality: Exogenous Testosterone and its precursors (DHEA, androstenedione, androstenediol) are strictly prohibited at all times under WADA S1.1. So-called 'Testosterone Replacement Therapy (TRT)' or 'Testosterone Optimization' in eugonadal athletes without organic hypothalamic-pituitary-testicular pathology is a prohibited doping violation and causes severe cardiovascular, thrombotic, and reproductive harm.

5. Quality of Scientific Evidence

Evidence Assessment: PROHIBITED AT ALL TIMES (WADA S1.1) — Strictly Regulated Prescription Medicine for Organic Hypogonadism Only

6. Approved Medical Uses (Where Applicable)

Testosterone Undecanoate / Enanthate IP is indicated strictly for confirmed organic primary (testicular failure, Klinefelter syndrome, bilateral orchidectomy) or secondary (pituitary/hypothalamic tumour, Kallmann syndrome) male hypogonadism documented by two separate morning fasting serum testosterone measurements plus clinical symptoms.

7. Sports-Related Uses, Misuse Patterns & Contamination Risks

Illicit abuse of injectable testosterone esters, transdermal gels, or oral prohormones (DHEA, androstenedione—often sold in unregulated 'testosterone booster' supplements). Detected in anti-doping laboratories via the WADA Urinary Steroid Profile (Testosterone/Epitestosterone [T/E] ratio, 5alpha-/5beta-androstanediol ratios) and confirmed definitively by Gas Chromatography–Combustion–Isotope Ratio Mass Spectrometry (GC-C-IRMS), which distinguishes exogenous synthetic plant-derived ¹³C/¹²C carbon isotope ratios from endogenous cholesterol-derived testosterone.

8. Adverse Effects & Serious Safety Risks

Secondary polycythaemia / erythrocytosis (haematocrit >54%, markedly increasing stroke, DVT/PE, and myocardial infarction risk), severe HPG-axis suppression with testicular atrophy and azoospermia/infertility, gynaecomastia (via peripheral aromatisation to oestradiol), hypertension, sodium/fluid retention, worsening of obstructive sleep apnoea, benign prostatic hyperplasia (BPH) lower urinary tract symptoms, acne/androgenic alopecia, hepatotoxicity, and intramuscular oil-pulmonary microembolism (POME) with depot injections.

9. Contraindications & Precautions

Known or suspected carcinoma of the prostate or male breast, pregnancy and lactation (Category X), baseline haematocrit >50–54%, severe untreated obstructive sleep apnoea, decompensated heart failure, desire for near-term fertility (exogenous testosterone acts as a male contraceptive by suppressing intratesticular testosterone), and non-medical athletic use.

10. Drug Interactions

Potentiates oral anticoagulants (Warfarin, Acenocoumarol) requiring close INR monitoring; increases oedema with corticosteroids or ACTH; reduces blood glucose requirements in patients on insulin/antidiabetics.

11. Clinical & Laboratory Monitoring Considerations

In legitimate clinical hypogonadism: Haematocrit/haemoglobin at baseline, 3–6 months, and annually (stop therapy if Hct >54%), PSA and digital rectal examination in men >=40 years, serum total testosterone, lipid profile, and liver function tests. WADA Therapeutic Use Exemptions (TUEs) for testosterone are granted ONLY for documented organic structural/genetic etiology—never for functional or age/training-related low testosterone.

12. Dependence, Misuse or Withdrawal Concerns

High risk of post-cessation hypogonadotropic hypogonadism, severe depressive symptoms, sexual dysfunction, and dependence on exogenous administration.

13. Regulatory & Legal Status in India (CDSCO / Drugs Rules / NDPS / FSSAI)

Prescription-only Schedule H drug under the Drugs and Cosmetics Act, 1940 and Indian Pharmacopoeia (IP 2022).

14. Official WADA Prohibited-List Status

PROHIBITED AT ALL TIMES (In-Competition and Out-of-Competition) under WADA Prohibited List Category S1.1 (Anabolic Androgenic Steroids — including exogenous testosterone, its esters, DHEA, androstenedione, and epitestosterone [also listed under S5 Masking Agents]).

15. Authoritative Source References & Date of Last Verification